■等值免疫是用父系来源的胎儿抗原免疫抗原阴性妊娠个体的过程。尽管Rh系统包含许多抗原亚型(D,C,C,E,e),RhD抗原具有高度免疫原性。本研究旨在调查圣保罗医院千年医学院(SPHMMC)RhD致敏孕妇的围产期结局。埃塞俄比亚。
■从2016年9月11日至2021年9月10日,在SPHMMC对98名接受RhD同种免疫的孕妇进行了一项基于设施的回顾性横断面研究。采用SPSS26进行数据分析。描述性统计数据用于评估RhD同种免疫孕妇的围产期结局。费舍尔的精确检验用于确定哪种关联,P值<0.05被认为具有统计学意义。
■从98次怀孕(06-积水,92-非水肿)胎儿贫血的高风险,45.9%的病例的MCA-PSV高于1.5MoM。其中,21.42%的胎儿接受了宫内输血。在21例胎儿中进行了43例IUT。每个胎儿的输血次数中位数为2次。大约52.4%的输血胎儿患有严重贫血,中度贫血占28.6%。MCAPSV≥1.5MOM在诊断RhD致敏孕妇中重度贫血中的预测81%.同种免疫的一般新生儿存活率为93.8%,90.5%与IUT,50%有胎儿水肿,96.7%无积水。
■这项研究提供了证据,表明MCAPSV≥1.5MoM是未输血胎儿中重度贫血的适度预测因子。这项研究是朝着对埃塞俄比亚RhD致敏孕妇围产期结局进行更广泛,多中心研究的一步。由于IUT数据库中缺乏信息,因此需要进行额外的研究来评估输血后胎儿贫血的评估策略。
UNASSIGNED: Isoimmunization is a process of immunizing an antigen-negative pregnant individual with a paternally derived fetal antigen. Although the Rh systems contain many antigen subtypes (D, C, c, E, e), the RhD antigen is highly immunogenic. This research aimed to investigate the perinatal Outcome of pregnant women with RhD sensitization at St. Paul\'s Hospital Millennium Medical College (SPHMMC), Ethiopia.
UNASSIGNED: A facility-based retrospective cross-sectional study was conducted on 98 pregnant women with RhD alloimmunization at SPHMMC from September 11, 2016, to September 10, 2021. SPSS 26 was used for data analysis. Descriptive statistics were utilized to assess the perinatal outcome of pregnant women with RhD alloimmunization. Fisher\'s exact test was used to determine which association, and a P value <0.05 was considered statistically significant.
UNASSIGNED: From the 98 pregnancies (06 - hydropic, 92 - non-hydropic) at high risk for fetal anemia, 45.9% of cases had MCA-PSV above 1.5MoM. Among these, 21.42% of all fetuses received an intrauterine transfusion. Forty-three IUTs were performed in 21 fetuses. The median number of transfusions per fetus was two. About 52.4% of the transfused fetuses had severe anemia, and 28.6% had moderate anemia. Prediction of MCA PSV ≥1.5MOM in diagnosing moderate-severe anemia in pregnant women with RhD sensitization 81%. General neonatal survival of alloimmunizations was 93.8%, 90.5% with IUT, 50% with hydrops fetalis, and 96.7% without hydrops.
UNASSIGNED: This research provides evidence that MCA PSV ≥1.5MoM is modest predictor of moderate-severe anemia in untransfused fetuses. This study was a step toward the development of more extensive and multicenter studies on the Perinatal Outcome of pregnant women with RhD sensitization in Ethiopia. Extra studies are needed to evaluate strategies for estimates of fetal anemia after blood transfusion as a result of the absence of information on the IUT database.